First Header Logo Second Header Logo

Connection

Peter Clark to Neoplasm Metastasis

This is a "connection" page, showing publications Peter Clark has written about Neoplasm Metastasis.
Connection Strength

0.440
  1. Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
    View in: PubMed
    Score: 0.133
  2. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615.
    View in: PubMed
    Score: 0.102
  3. Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006 May; 18(3):277-83.
    View in: PubMed
    Score: 0.063
  4. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
    View in: PubMed
    Score: 0.035
  5. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-?B gene signature predicts prostate cancer progression. Cancer Res. 2014 May 15; 74(10):2763-72.
    View in: PubMed
    Score: 0.027
  6. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11.
    View in: PubMed
    Score: 0.023
  7. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One. 2011; 6(8):e22486.
    View in: PubMed
    Score: 0.023
  8. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006 Sep 1; 107(5):1093-100.
    View in: PubMed
    Score: 0.016
  9. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
    View in: PubMed
    Score: 0.013
  10. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol. 1995 Mar; 153(3 Pt 2):981-5.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.